Full Papers
The European Ankylosing Spondylitis Infliximab Cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab
F. Heldmann, J. Brandt, I. Van der horst-Bruinsma, R. Landewe, J. Sieper, G.R. Burmester, F. Van Den Bosch, K. De Vlam, P. Geusens, H. Gaston, S. Schewe, T. Appelboom, P. Emery, M. Dougados, M. Leirisalo-Repo, M. Breban, J. Listing, J. Braun
CER4442
2011 Vol.29, N°4
PI 0672, PF 0680
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 21906431 [PubMed]
Received: 09/01/2011
Accepted : 07/04/2011
In Press: 31/08/2011
Published: 31/08/2011
Abstract
OBJECTIVES:
To study the long-term efficacy and safety of treatment with infliximab in patients with ankylosing spondylitis (AS) in a real life setting.
METHODS:
AS patients from 6 European countries who had finished the 2-year trial ASSERT were invited to participate in the open- label investigator-driven study EASIC. At baseline, 2 groups were formed: patients of group 1 had not been treated with infliximab after ASSERT, while those of group 2 had continuously received it. Patients of group 1 were further subdivided in group 1a: patients with a relapse and 1b: in remission. All patients of group 1a and 2 continuously received infliximab for 96 weeks, mean dose 5 mg/kg, intervals 6–8 weeks. Patients of group 1b were also treated in case of relapse.
RESULTS:
A total of 103/149 patients (69%) were included in EASIC, 1.3±0.9 years after the end of ASSERT: 9 in group 1a, 5 in group 1b and 89 in group 2. Most patients were male (83%), mean age 44 years. Most patients of group 2 completed the trial (86%) vs. only 5 of group 1 (33%) – mostly due to allergic reactions after readministration of infliximab. In total, there were 22 drop-outs due to 6 adverse events, 4 lack of efficacy, 3 planned pregnancy. All standard assessments indicated beneficial values over time, at week 96 significantly better than at baseline of ASSERT.
CONCLUSIONS:
The majority of patients were continuously and successfully treated with infliximab for 5 years, whereas discontinuation and reintroduction of therapy was less satisfactory due to the frequent occurrence of hypersensitivity reactions. Anti-TNF therapy with infliximab proved to be effective and safe on a long-term basis.